Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Evans

Showing results (21-30 of 208) with videos related to

Pageof 21
Sort By:
Therapeutics and Clinical Risk Management|March 25, 2008
Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)Angelo J Cambio, Christopher P Evans
The Lancet. Oncology|November 12, 2013
Dasatinib and docetaxel in advanced prostate cancerPrimo N Lara, Christopher P Evans
JAMA Oncology|December 14, 2018
Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to BePrimo N Lara, Christopher P Evans
European Urology|September 8, 2006
Minimising postoperative incontinence following radical prostatectomy: considerations and evidenceAngelo J Cambio, Christopher P Evans
European Urology|April 30, 2017
Adjunct Screening of NKX3.1 Expression Supports 5α-Reductase Inhibition Intervention in Prostate Cancer Active SurveillanceJoy C Yang, Christopher P Evans
Urologic Oncology|December 30, 2008
Oncogenic activation of androgen receptorHsing-Jien Kung, Christopher P Evans
The Journal of Urology|July 11, 2003
Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasiaPerinchery Narayan, Christopher P Evans, Timothy Moon
Urologic Oncology|September 7, 2010
What is the optimal management of high risk, clinically localized prostate cancer?James A Eastham, Christopher P Evans, Anthony Zietman
World Journal of Urology|September 7, 2002
Minimally invasive therapies for benign prostatic hyperplasiaHari Siva Gurunadha Rao Tunuguntla, Christopher P Evans
Current Opinion in Urology|March 6, 2012
Economic analysis of active surveillance for localized prostate cancerSun Kim, Marc A Dall'Era, Christopher P Evans
Pageof 21

Showing results (21-30 of 208) with videos related to

Sort By:
Pageof 21
Therapeutics and Clinical Risk Management|March 25, 2008
Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)Angelo J Cambio, Christopher P Evans
The Lancet. Oncology|November 12, 2013
Dasatinib and docetaxel in advanced prostate cancerPrimo N Lara, Christopher P Evans
JAMA Oncology|December 14, 2018
Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to BePrimo N Lara, Christopher P Evans
European Urology|September 8, 2006
Minimising postoperative incontinence following radical prostatectomy: considerations and evidenceAngelo J Cambio, Christopher P Evans
European Urology|April 30, 2017
Adjunct Screening of NKX3.1 Expression Supports 5α-Reductase Inhibition Intervention in Prostate Cancer Active SurveillanceJoy C Yang, Christopher P Evans
Urologic Oncology|December 30, 2008
Oncogenic activation of androgen receptorHsing-Jien Kung, Christopher P Evans
The Journal of Urology|July 11, 2003
Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasiaPerinchery Narayan, Christopher P Evans, Timothy Moon
Urologic Oncology|September 7, 2010
What is the optimal management of high risk, clinically localized prostate cancer?James A Eastham, Christopher P Evans, Anthony Zietman
World Journal of Urology|September 7, 2002
Minimally invasive therapies for benign prostatic hyperplasiaHari Siva Gurunadha Rao Tunuguntla, Christopher P Evans
Current Opinion in Urology|March 6, 2012
Economic analysis of active surveillance for localized prostate cancerSun Kim, Marc A Dall'Era, Christopher P Evans
Pageof 21